Navigation Links
Pearl Therapeutics Announces Positive Results for Phase 2b Dose-Ranging Study of Formoterol MDI
Date:8/30/2011

REDWOOD CITY, Calif., Aug. 30, 2011 /PRNewswire/ -- Pearl Therapeutics Inc. today announced positive results from a randomized, double-blind, Phase 2b, dose-ranging study of its formoterol fumarate metered dose inhaler (FF MDI; PT005), a long-acting beta-2 agonist (LABA) compared to placebo and Foradil® Aerolizer® in patients with moderate-to-severe COPD. All doses of FF MDI tested produced highly statistically significant improvements in lung function (FEV1 AUC 0-12) compared to placebo (p<0.0001). Dose ordering (incremental increase in efficacy with increasing doses) was observed across the three FF MDI doses evaluated, and the two lower doses tested were comparable to 12 mcg Foradil, the currently approved dose. This study marks the fourth in a series of detailed clinical evaluations of FF by Pearl in its novel MDI formulation platform, and significantly expands the safety and efficacy database of FF MDI. Detailed results of this study will be presented at a future conference.

"Successful completion of this study is an important milestone in the development of PT003, Pearl's combination of FF with glycopyrrolate, a long acting muscarinic antagonist (LAMA). The dose ordering and consistent response observed in this study confirm the robustness of Pearl's breakthrough formulation platform, and strengthen the value of FF MDI as the LABA arm of the PT003 program," commented Colin Reisner, Pearl's chief medical officer and executive vice president of clinical development. "The totality of data from this and previous studies provides Pearl with the confidence to select a dose of FF MDI to progress into PT003 Phase 3 studies."

Chuck Bramlage, Pearl's chief executive officer added, "This study was completed in only three months, demonstrating the drive of the Pearl development
'/>"/>

SOURCE Pearl Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Pearl Therapeutics Advances Its Long-Acting Bronchodilator Combination Product Candidate into Four Additional Phase 2 Studies
2. Pearl Therapeutics Phase 2b Results Show a 50% Improvement in Lung Function with PT003 Compared to Spiriva® and Foradil® in Patients with COPD
3. Asante Solutions Receives FDA Clearance for Pearl™ Insulin Pump
4. Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
5. Pearl Therapeutics to Present Complete PT003 Results from Phase 2b COPD Study in a Late-Breaker Session at the American Thoracic Society Annual Meeting
6. Asante Solutions, Inc. Receives CE Mark for Pearl™ Insulin Pump
7. Prime Therapeutics Drug Trend Insights Reports One of the Lowest Drug Spending Increases in the Industry
8. Precision Therapeutics Named on Inc. 500
9. 5000 2011 List and Recognized for Achievements in Personalized Medicine Industry
10. Cell Therapeutics Submits Day 120 Response for Pixantrone Marketing Authorization Application to European Medicines Agency; Potential Q1 2012 Opinion on Approval
11. Inhibikase Therapeutics Receives FDA Clearance for Phase II Trial of IkT-001 to Treat JC Virus Infection, the Cause of Progressive Multifocal Leukoencephalopathy (PML) in Multiple Sclerosis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... LONDON , BERLIN ... 2013 Arthroscopy Devices Market ... Preference for Minimally Invasive Procedures to Drive Future Growth" ... trends for the six arthroscopy device market segments: arthroscopes, ... arthroscopy radio frequency systems, and arthroscopy visualization systems. The ...
(Date:5/20/2013)... 20, 2013  Rhythm announced today the presentation of ... prevalence of gastroparesis symptoms among diabetic patients in the ... high among patients with both type 1 and type ... those with the more common type 2 disease. ... PhD, Associate Professor of Medicine at Harvard Medical School ...
(Date:5/20/2013)... 2013  AbbVie (NYSE: ABBV ) ... clinical study called SONAR (Study Of Diabetic Nephropathy ... investigational compound atrasentan - when added to standard of ... with stage 2 to 4 chronic kidney disease ... large, multinational, double-blind, placebo-controlled clinical study that is ...
Breaking Medicine Technology:Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 2Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 3Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 4Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 2Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 3Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 2AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 3AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 5AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 6
(Date:5/20/2013)... 20, 2013 Gilman Law LLP, a ... investigating Byetta lawsuits, is troubled by a new study ... and similar type 2 diabetes drugs are growing. ... Practices (ISMP), found that 71 Byetta pancreatic cancer reports ... Administration (FDA) as of June 30, 2012. ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 Headquartered in ... Levy Phillips & Konigsberg LLP (“LPK”) has ... White Plains, New York. LPK will better serve people ... Hudson Valley, including Westchester, Putnam, Rockland, Orange, and Dutchess ... affected by asbestos-related diseases throughout New York, New Jersey, ...
(Date:5/20/2013)... Online education provides the convenience, ... does not offer. According to the American Heart ... switching classroom learning to eLearning due to changing ... helped maximize training budgets, but it is also ... by 25–60%. A higher retention of content is ...
(Date:5/20/2013)... comprised over 24,000 Finnish subjects and was led ... a panel of 28 genetic markers improved detection ... disease (CHD) (10-year risk ≥20%) over traditional risk ... important preventive strategy for CHD, because the current ... "The results indicate that genetic markers could be ...
(Date:5/20/2013)... when a particular strain of avian influenza might become ... to be published in the International Journal Data ... University of Arizona, Tucson, and colleagues at the Huazhong ... Institute of Virology, explain that since 1997 several strains ... "bird flu" have infected people directly from their natural ...
Breaking Medicine News(10 mins):Health News:Byetta Lawyers at Gilman Law, a Leading Pharmacy Law and Defective Drug Plaintiffs’ Law Firm, Troubled by Growing Byetta Pancreatic Cancer Reports 2Health News:Byetta Lawyers at Gilman Law, a Leading Pharmacy Law and Defective Drug Plaintiffs’ Law Firm, Troubled by Growing Byetta Pancreatic Cancer Reports 3Health News:Westchester Mesothelioma Lawyers Open Office in White Plains, New York 2Health News:Westchester Mesothelioma Lawyers Open Office in White Plains, New York 3Health News:Swank HealthCare Announces New Offering of Additional American Heart Association’s Accredited Online Courses 2Health News:Predicting infectious influenza 2
... TV Ad Rebrands California Republican Party as the ,Yacht Party, for ... Supporting ,Yacht Tax, ... Courage Campaign have released a new ad branding the California,Republican Party ... that allows buyers of yachts and private jets to avoid paying,sales ...
... sellout for Actifirm(R), a,leading manufacturer of science-based skin ... on QVC Saturday, May 10., QVC program ... six Actifirm products, including 10% Z-Peel(R); Face Firm(TM);,Renovation ... discovery kit with Actifirm products for cleansing, exfoliating,and ...
... CMS Regulatory Action a,Serious Public Policy Misstep; Seniors, Nursing ... OH, IL, PA, NJ, MI, MA, WASHINGTON, May ... the Bush Administration,s $770 million cut to,Medicare-financed nursing home ... regulatory-driven cuts not only jeopardize seniors,access to quality nursing ...
... children exposed to tobacco smoke respond particularly well ... Jewish Medical and Research Center. Associate Professor ... also identified two biomarkers that may help physicians ... from montelukast. , These findings will help doctors ...
... - Significant Increase by 31,6% in Sales and 10,3 % in Net ... 31,6% of the Consolidated Sales to EUR 11,3m in the First ... - Increased by 12,7% of the Consolidated EBITDA to EUR 2,6m (from ... Net Profits (EAT) Increased by 10,3% to EUR 1,5m (from EUR 1,4m in ...
... Pepper Award nominations, DETROIT, May 13 ... lives of Michigan,s senior citizens have until June ... Shield of Michigan,s Claude,Pepper Award., The award ... volunteer efforts have made significant contributions to improving ...
Cached Medicine News:Health News:California Nurses Association, Courage Campaign, Arianna Huffington Team up for 'Yacht Party 2' TV Ad 2Health News:California Nurses Association, Courage Campaign, Arianna Huffington Team up for 'Yacht Party 2' TV Ad 3Health News:Actifirm Sells Out in First Hour Appearance on QVC 2Health News:New Studies of Bush Administration $770 Million SNF Medicare Cut Find Seniors' Care Jeopardized, Local Jobs Lost, National and State Economies Threatened 2Health News:New Studies of Bush Administration $770 Million SNF Medicare Cut Find Seniors' Care Jeopardized, Local Jobs Lost, National and State Economies Threatened 3Health News:New Studies of Bush Administration $770 Million SNF Medicare Cut Find Seniors' Care Jeopardized, Local Jobs Lost, National and State Economies Threatened 4Health News:Girls and children exposed to tobacco smoke benefit more from montelukast (singulair) 2Health News:KORRES Q1 2008 Results 2Health News:Blue Cross Blue Shield of Michigan Seeking Nominations for Outstanding Senior Advocates 2
... TM-1 is a compact multi-functional ... precise measurement of UVA, UVB, ... all types of lens materials. ... connect with a personal computer ...
... This sleek, contoured instrument table ... room dcor, while providing a sturdy, ... wheelchair compatible design provides completely open ... make positioning quick and easy. The ...
If youre looking to expand your projection capabilities, without a major capital investment, consider Topcons CP-5D Chart Projector....
... corrected curve trial lenses are ground with the ... refractors and are invaluable in treating low vision ... manufacturers contain a disproportionately large number of lenses ... to produce, and fewer lenses in the higher ...
Medicine Products: